AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05440851 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Usual care without routine corticosteroids
Description: Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
Study NCT05440851 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Usual care without extending corticosteroids
Description: Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
Study NCT06427889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canoderm
Description: humectant
Study NCT06427889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oviderm
Description: humectant + antimicrobial
Study NCT06427889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decubal
Description: Non-humectant
Study NCT05645341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: screening system for ocular surface malignant tumors
Description: Develop an intelligent screening system for ocular surface malignant tumors, apply it to the mobile terminal for real-world verification and large-scale general screening, and test its effect on assisting doctors in the diagnosis and treatment of rare diseases.
Study NCT04687462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
Description: TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
Study NCT04687462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
Description: TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
Study NCT06032728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: The investigators randomly assign multimodal recurrence scoring system defined high risk patients of stage III ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation
Study NCT05299866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
Study NCT05299866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After surgery, patient-controlled analgesia is provided. The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
Study NCT04795635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMM + Axon Therapy
Description: transcutaneous magnetic stimulation (tMS)
Study NCT06473350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The application of right lateral, supine, and prone positions to preterm infants after feeding
Description: Each infant included in the sample group is fed at their routine feeding time (9:00 a.m.), followed by placement in the right lateral position. Immediately after this position is applied, as well as one hour and three hours later, data on heart rate, oxygen saturation, respiratory rate, pain level, and comfort level are recorded. This procedure is repeated after the subsequent feeding time (12:00 p.m.) for the supine position and after the feeding time following that (6:00 p.m.) for the prone position. This procedure is repeated for three consecutive days at the same feeding times and in the same sequence.
Study NCT05731115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental 23-valent Pneumococcal
Description: The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.
Study NCT05588531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1:YK-1169
Description: YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours
Study NCT05588531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2:YK-1169/Placebo Injection
Description: YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours
Study NCT05588531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 3:YK-1169/Placebo
Description: On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
Study NCT05588531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 4:YK-1169/Placebo
Description: On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
Study NCT05588531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 5:YK-1169/Placebo Injection
Description: YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours
Study NCT05588531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injection
Description: YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours
Study NCT05859217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral once per day, Days 1 - 21 every 21 days
Study NCT05859217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous (IV) once every 21 days
Study NCT05332223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Full Polysomnography
Description: Overnight PSG will be conducted using Alice version 6 system (Respironics, Pittsburgh, PA, USA). During PSG, the following variables will be monitored and captured. Sleep staging using electroencephalogram (four channels: C3-A2, C4-A1, O1-A2, O2-A1), electrooculogram (two channels: LOC-A2, ROC-A1), electromyogram (two channels: submental and anterior tibialis muscles). Respiratory effort using inductive plethysmograph sensors to detect thoracoabdominal movements. Oro-nasal airflow using pressure flow transducer and thermistor. Oxygen saturation using pulse oximetry and cardiac rhythm using electrocardiography. Other parameters that will also be monitored includes body position, presence of snoring and end tidal CO2 (EtCO2) measurement to detect hypercapnia. The attended PSG will be conducted in the sleep laboratory in Respiratory Unit, Hospital Taiping
Study NCT06183138 — intervention group
Intervention type: GENETIC
Intervention: Genomic sequencing
Description: Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
Study NCT05826470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRANBERG®|Thermal Therapy System
Description: Focal laser ablation.
Study NCT05651867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPIONE device
Description: The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
Study NCT05043922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYH33
Description: a Selective PI3Kα Inhibitor
Study NCT04893252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab and vactosertib
Description: durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week)
Study NCT05059743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Larotinib
Description: Patients will receive single dose of orally \[14C\]-Larotinib on Day 1.
Study NCT05847673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Smoking Cessation Intervention
Description: Receive EQQUAL A intervention
Study NCT05847673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Smoking Cessation Intervention
Description: Receive EQQUAL B intervention
Study NCT05847673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05847673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04052828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)
Description: This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
Study NCT05847673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive motivational messages and smoking cessation information via SMS text messages
Study NCT05847673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion and Education
Description: Receive motivational messages and smoking cessation information via SMS text messages
Study NCT04669015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novaferon
Description: a novel recombinant antiviral protein drug
Study NCT04669015 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation vehicle
Study NCT05013424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Intramuscular Injection
Study NCT04911894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI321
Description: Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
Study NCT05269745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching through immobilisation (IG)
Description: The immobilization group (IG) will receive the standard treatment, a dynamic ankle-foot orthosis (AFO) for night and day use (23 hours per day)
Study NCT05269745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching through immobilisation and activity (IAG)
Description: The Immobilization/Activity Group (IAG) will be treated with the same type of ankle-foot orthosis at night (8 hours) and for 6 hours during the day (altogether orthosis treatment 14 hours per day). The rest of the day (10 hours) children and adolescents will be using only the foot shell of orthoses (FS) without the lower leg shell, to secure the correct position of the foot and to allow a free motion at ankle joint with a good correction of the foot deformity (e.g. Pes equinovarus / equinovalgus, midfoot-break).
Study NCT05269745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Phase
Description: Before the intervention with the orthotic treatment starts, a control phase of 8 weeks is planned. During this time, the individual orthoses for each subject are manufactured.
Study NCT06147297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuned In
Description: The Tuned In programme is based on Russell's (1980) circumplex model of emotion, which categories emotions along the two dimensions of valence and arousal. Through psychoeducation and group discussions, participants in the programme first learn how to categorise their emotions in terms of intensity (i.e., arousal level) and positivity (i.e., valence). They then reflect on and develop a list of songs that they relate to personally and use them to increase or decrease the intensity and positivity of their emotions. In other words, the participants practise monitoring their emotional state and use music to help them modify how they feel. The programme will be conducted by a facilitator with a psychology background, and a registered music therapist.
Study NCT06198348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic Exercise
Description: Treatment Protocol to Group A It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 30 minutes.~It will include warm up phase, active phase and cool down phase Warm-up phase:~In which each participant will walk at 80 m/min at for 5 min.~Active phase:~Brisk walking or treadmill:~In which each participant will perform brisk walking for 15 mints initially. After that gradually duration of brisk walking will increase.
Study NCT06198348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises with Resistance training
Description: These groups will perform these exercises:~Aerobic exercise +resistance exercises Exercise~Session: 3 days per week Time of exercise session: 30-45 min~After following protocol of aerobic exercise as mentioned above the subjects will perform resistance exercises. These Exercises will perform:~1. Leg press (dual leg press):~   Leg press targets the Glutes Quadriceps or quads .but they also work your Hamstrings.~2. Crunches:~   Crunches Target the abdominal muscles specifically rectus abdominis and obliques.~3. Squats:~Squats targets the adductor muscles of the hip, glutes and rectus abdominis muscle Leg Extension~Total Exercise plan for 12 weeks:~1-2 weeks: Repitations: 10-15 times~No of sets: 1 set Resistance: minimum 3-4 weeks:~Repitations: 10-15 times~No of sets: 2 set Resistance: moderate 5-6 weeks:~Repitations: 15-16 times~No of sets: 2 set Resistance: moderate 7-8 weeks:~Repitations: 15-16 times No of sets: 2 set
Study NCT05301491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance Therapy Group
Description: Dance therapy group patients are going to be treated 3 days a week for 8 weeks. Patients who started treatment are going to be randomly divided into groups that includes four individuals, due to COVID-19 pandemic preventions.~Dance therapy is going to be applied with individualized choreographies specially prepared for the patients, taking the expert opinion of the dance therapist. Choreographies of different dance genres (step/aerobic dance, zumba, salsa, bachata, oriental etc.) are going to be used in the program. Sessions are going to be with the practitioner in a bright, clean, empty and noiseless room in front of a full-length wall mirror. The practitioner is going to participate to dance therapy throughout the sessions, allowing patients to imitate movements. Session duration is going to be 40 minutes. Patients will be given a one-minute rest period during music transitions.
Study NCT05301491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The patients in the control group is going to perform conventional low back exercises. The program of the patients will start with stretching and warming exercises, and will continue with strengthening exercises.~Exercises planed for control group;~1. Unilateral hip-knee flexion (self-assisted exercise)~2. Bilateral hip-knee flexion (self-assisted exercise)~3. Straight leg lifting with the aid of a sheet/rigid band~4. Posterior pelvic tilt~5. Bridge building exercise~6. Cat-camel exercise~7. Half shuttle in sagittal plane~8. Right and left rotational shuttle~9. Trunk hyperextension in prone position~10. Rotational exercise with hip-knee flexed in supine position Patients are going to do exercises with ten repetitions. As the sessions progressed, the number of repetitions will be increased.
Study NCT05301491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyhsiotherapy Modalities
Description: 20 minutes hotpack, 3-5 minutes ultrasound and 20 minutes conventional type Transcutaneous Electrical Nerve Stimulation (TENS) are going to be applied to lumbar region of all patients in prone position.
Study NCT04721613 — intervention group
Intervention type: OTHER
Intervention: Assessment of Melatonin level
Description: Measuring the plasma or serum melatonin in pg/ml during the first 24 hours after delirium diagnosis in two-hour intervals.
Study NCT05084859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM08502
Description: SM08502 to be administered orally.
Study NCT05084859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone to be administered orally.
Study NCT05084859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone to be administered orally.
Study NCT05084859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel to be administered intravenously.
Study NCT05084859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: FOLFIRI Protocol to be administered intravenously.
Study NCT05084859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab to be administered intravenously.
Study NCT05985785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow aspirate concentrate (BMAC)
Description: Bone marrow aspirate concentrate BMAC is a biologically substance harvested from a patient for autologous use. Bone marrow aspirate concentrate (BMAC) has been determined by the FDA to be a minimally manipulated biologic prepared for autologous use and does not require premarket FDA approval for clinical use.
Study NCT05985785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injections
Description: Current standard of treatment for OA of the knee is corticosteroid injection.
Study NCT05985785 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Crossover Autologous bone marrow aspirate concentrate (BMAC)
Description: Subjects who participate in this study and who are randomized to receive the BMAC may experience decreased pain and increased functionality after the injection compared to those that receive a corticosteroid injection. As such, participants who continue to have pain after a corticosteroid injection will be allowed to crossover to a BMAC injection at 24 weeks or 6 months post-surgery.(ARM 3)
Study NCT04723238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg Test Drug Enteric Coated Granules
Description: Investigational Medicinal Product
Study NCT04723238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60mg Reference Product Enteric Coated Granules
Description: Cymbalta (Eli Lilly)
Study NCT06641973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic balance rehabilitation with hunova® robotic platform
Description: The G-Hun will perform robotic balance treatment with the hunova® robotic platform lasting 30 minutes per session, 2 times a week for 5 weeks, in addition to the services provided in their clinical pathway.
Study NCT06250790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography and FFRct analysis
Description: A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
Study NCT05551325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronobundle - light
Description: Bright daytime light from 09:00 to 13:00 starting on day 1. The light will be 10,000 lux at 12 and provide a minimal intensity of 1,250 lux at the angle of the eye (30 to 36 distance). The light has a temperature of 5,000 Kelvin indicating a high blue wavelength content which should maximize circadian effects (validated device Sunbox Lighting, Maryland). Following the 09:00 to 13:00 bright light, the room lights will remain on and the curtains will remain open to maximize daytime light exposure while not decreasing bright light tolerance.
Study NCT05551325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chronobundle - feeding
Description: For patients receiving enteral feeds, time-restricted (daytime) intermittent feeding will include 4 meals delivered at 08:00, 12:00, 16:00 and 20:00. Each meal will include one-fourth of the recommended daily tube feed volume.
Study NCT05551325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chronobundle - mobility
Description: While in the MICU, exercise/mobility sessions led by physical therapy or occupational therapy providers will occur twice daily between 09:00 and 16:00 (i.e., one additional session beyond usual care); intensity will be determined by clinical status and documented in the chart by our physical therapy service. Patients in other hospital locations (e.g., general medical ward post-MICU discharge) will receive one additional session beyond usual care via a study staff-led exercise/mobility session; intensity will be determined by clinical status.
Study NCT05551325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chronobundle - sleep
Description: Overnight sleep promotion will occur between 22:00 and 06:00 with a more restricted sleep period between 00:00 and 04:00. This will be achieved by rescheduling non-urgent care. There will be no changes to urgent care. Additionally, room lights will be dimmed, curtains drawn, and room doors closed. Television screens will be fitted with blue light-blocking filters.